These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26749503)

  • 1. Complement activation in leprosy: a retrospective study shows elevated circulating terminal complement complex in reactional leprosy.
    Bahia El Idrissi N; Hakobyan S; Ramaglia V; Geluk A; Morgan BP; Das PK; Baas F
    Clin Exp Immunol; 2016 Jun; 184(3):338-46. PubMed ID: 26749503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal.
    Khadge S; Banu S; Bobosha K; van der Ploeg-van Schip JJ; Goulart IM; Thapa P; Kunwar CB; van Meijgaarden KE; van den Eeden SJ; Wilson L; Kabir S; Dey H; Goulart LR; Lobato J; Carvalho W; Bekele Y; Franken KL; Aseffa A; Spencer JS; Oskam L; Otttenhoff TH; Hagge DA; Geluk A
    BMC Infect Dis; 2015 Oct; 15():477. PubMed ID: 26510990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Situ complement activation and T-cell immunity in leprosy spectrum: An immunohistological study on leprosy lesional skin.
    Bahia El Idrissi N; Iyer AM; Ramaglia V; Rosa PS; Soares CT; Baas F; Das PK
    PLoS One; 2017; 12(5):e0177815. PubMed ID: 28505186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. M. leprae components induce nerve damage by complement activation: identification of lipoarabinomannan as the dominant complement activator.
    Bahia El Idrissi N; Das PK; Fluiter K; Rosa PS; Vreijling J; Troost D; Morgan BP; Baas F; Ramaglia V
    Acta Neuropathol; 2015 May; 129(5):653-67. PubMed ID: 25772973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terminal complement complex in plasma of leprosy patients.
    Parkash O; Katoch K; Sengupta U
    Acta Leprol; 1990; 7(3):221-4. PubMed ID: 2099585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local and systemic activation of the whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers.
    Dauchel H; Joly P; Delpech A; Thomine E; Sauger F; Le Loet X; Lauret P; Tron F; Fontaine M; Ripoche J
    Clin Exp Immunol; 1993 May; 92(2):274-83. PubMed ID: 8485913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased chitotriosidase activity in serum of leprosy patients: association with bacillary leprosy.
    Iyer A; van Eijk M; Silva E; Hatta M; Faber W; Aerts JM; Das PK
    Clin Immunol; 2009 Jun; 131(3):501-9. PubMed ID: 19307157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activation of neutrophils by suspensions of Mycobacterium leprae.
    Goihman-Yahr M; Rodriguez-Ochoa G; Aranzazu N; Pinardi ME; de Gomez ME; Ocanto A; Convit J
    Int J Lepr Other Mycobact Dis; 1979 Dec; 47(4):570-4. PubMed ID: 122626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating cytokine profiles in leprosy patients.
    Belgaumkar VA; Gokhale NR; Mahajan PM; Bharadwaj R; Pandit DP; Deshpande S
    Lepr Rev; 2007 Sep; 78(3):223-30. PubMed ID: 18035773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of Mycobacterium leprae unique antigens in leprosy endemic populations in Asia and Africa.
    Bobosha K; Van Der Ploeg-Van Schip JJ; Zewdie M; Sapkota BR; Hagge DA; Franken KL; Inbiale W; Aseffa A; Ottenhoff TH; Geluk A
    Lepr Rev; 2011 Dec; 82(4):445-58. PubMed ID: 22439283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-PGL1 salivary IgA/IgM, serum IgG/IgM, and nasal Mycobacterium leprae DNA in individuals with household contact with leprosy.
    Brito e Cabral P; Júnior JE; de Macedo AC; Alves AR; Gonçalves TB; Brito e Cabral TC; Gondim AP; Pinto MI; Oseki KT; Camara LM; Rabenhorst SH; Nagao-Dias AT
    Int J Infect Dis; 2013 Nov; 17(11):e1005-10. PubMed ID: 23871279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole blood RNA signatures in leprosy patients identify reversal reactions before clinical onset: a prospective, multicenter study.
    Tió-Coma M; van Hooij A; Bobosha K; van der Ploeg-van Schip JJ; Banu S; Khadge S; Thapa P; Kunwar CB; Goulart IM; Bekele Y; Hagge DA; Moraes MO; Teles RMB; Pinheiro RO; van Zwet EW; Goeman JJ; Aseffa A; Haks MC; Ottenhoff THM; Modlin RL; Geluk A
    Sci Rep; 2019 Nov; 9(1):17931. PubMed ID: 31784594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between detection delay and impairment in leprosy control: a comparison of patient cohorts from Bangladesh and Ethiopia.
    Van Veen NH; Meima A; Richardus JH
    Lepr Rev; 2006 Dec; 77(4):356-65. PubMed ID: 17343222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic and functional features of innate and adaptive immunity as putative biomarkers for clinical status and leprosy reactions.
    Carvalho JC; Araújo MG; Coelho-Dos-Reis JGA; Peruhype-Magalhães V; Alvares CC; Moreira ML; Teixeira-Carvalho A; Martins-Filho OA; Araújo MSS
    Microb Pathog; 2018 Dec; 125():230-239. PubMed ID: 30195647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A potential role for complement in immune evasion by Mycobacterium leprae.
    Callegaro-Filho D; Shrestha N; Burdick AE; Haslett PA
    J Drugs Dermatol; 2010 Nov; 9(11):1373-82. PubMed ID: 21061760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum samples from patients with mycobacterial infections cross-react with HIV structural proteins Gp41, p55 and p18.
    Hussain T; Sinha S; Katoch K; Yadav VS; Kulshreshtha KK; Singh I; Sengupta U; Katoch VM
    Lepr Rev; 2007 Jun; 78(2):137-47. PubMed ID: 17824484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leprosy as a model of immunity.
    Degang Y; Nakamura K; Akama T; Ishido Y; Luo Y; Ishii N; Suzuki K
    Future Microbiol; 2014; 9(1):43-54. PubMed ID: 24328380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of new host biomarker profiles in quantitative point-of-care tests facilitates leprosy diagnosis in the field.
    van Hooij A; van den Eeden S; Richardus R; Tjon Kon Fat E; Wilson L; Franken KLMC; Faber R; Khatun M; Alam K; Sufian Chowdhury A; Richardus JH; Corstjens P; Geluk A
    EBioMedicine; 2019 Sep; 47():301-308. PubMed ID: 31422044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of Mycobacterium leprae DNA and PGL-1 antigen in household contacts of leprosy patients from a hyperendemic area in Brazil.
    Pinho JD; Rivas PM; Mendes MB; Soares RE; Costa GC; Nascimento FR; Paiva MF; Aquino DM; Figueireido IA; Santos AM; Pereira SR
    Genet Mol Res; 2015 Nov; 14(4):14479-87. PubMed ID: 26600506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudomonas aeruginosa Uses Dihydrolipoamide Dehydrogenase (Lpd) to Bind to the Human Terminal Pathway Regulators Vitronectin and Clusterin to Inhibit Terminal Pathway Complement Attack.
    Hallström T; Uhde M; Singh B; Skerka C; Riesbeck K; Zipfel PF
    PLoS One; 2015; 10(9):e0137630. PubMed ID: 26368530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.